NZ514488A - Vascular endothelial cell growth factor variants and uses thereof - Google Patents

Vascular endothelial cell growth factor variants and uses thereof

Info

Publication number
NZ514488A
NZ514488A NZ514488A NZ51448800A NZ514488A NZ 514488 A NZ514488 A NZ 514488A NZ 514488 A NZ514488 A NZ 514488A NZ 51448800 A NZ51448800 A NZ 51448800A NZ 514488 A NZ514488 A NZ 514488A
Authority
NZ
New Zealand
Prior art keywords
growth factor
cell growth
vascular endothelial
endothelial cell
factor variants
Prior art date
Application number
NZ514488A
Other languages
English (en)
Inventor
Brian Cunningham
Devos Abraham
Bing Li
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ514488A publication Critical patent/NZ514488A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ514488A 1999-04-16 2000-04-10 Vascular endothelial cell growth factor variants and uses thereof NZ514488A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12978899P 1999-04-16 1999-04-16
US18423500P 2000-02-23 2000-02-23
PCT/US2000/009483 WO2000063380A1 (en) 1999-04-16 2000-04-10 Vascular endothelial cell growth factor variants and uses thereof

Publications (1)

Publication Number Publication Date
NZ514488A true NZ514488A (en) 2004-01-30

Family

ID=26827914

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514488A NZ514488A (en) 1999-04-16 2000-04-10 Vascular endothelial cell growth factor variants and uses thereof

Country Status (15)

Country Link
US (1) US20060063203A1 (cg-RX-API-DMAC7.html)
EP (2) EP1655368B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002541849A (cg-RX-API-DMAC7.html)
KR (1) KR100634926B1 (cg-RX-API-DMAC7.html)
CN (1) CN1328376C (cg-RX-API-DMAC7.html)
AT (2) ATE329024T1 (cg-RX-API-DMAC7.html)
AU (1) AU771042B2 (cg-RX-API-DMAC7.html)
CA (1) CA2370246C (cg-RX-API-DMAC7.html)
DE (2) DE60041367D1 (cg-RX-API-DMAC7.html)
ES (2) ES2265931T3 (cg-RX-API-DMAC7.html)
HU (1) HU228898B1 (cg-RX-API-DMAC7.html)
IL (2) IL145675A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010469A (cg-RX-API-DMAC7.html)
NZ (1) NZ514488A (cg-RX-API-DMAC7.html)
WO (1) WO2000063380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド eNOS活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
JP2005519980A (ja) 2002-03-01 2005-07-07 ブラッコ インターナショナル ビー.ヴイ. 治療および診断用途の多価構成物
SI2301587T1 (sl) * 2002-03-01 2014-11-28 Dyax Corp. KDR in VEGF/KDR vezavni peptidi in njihova uporaba pri diagnozi
IL165392A0 (en) 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
HUE029170T2 (en) 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169292A (en) * 1875-10-26 Improvement in butter-packages
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
CN1185159A (zh) * 1995-06-06 1998-06-17 人体基因组科学有限公司 人血管内皮生长因子3
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Also Published As

Publication number Publication date
IL145675A (en) 2010-11-30
HUP0200827A2 (en) 2002-06-29
EP1655368A1 (en) 2006-05-10
JP2002541849A (ja) 2002-12-10
ES2265931T3 (es) 2007-03-01
CN1352684A (zh) 2002-06-05
EP1171594B1 (en) 2006-06-07
IL145675A0 (en) 2002-06-30
CA2370246A1 (en) 2000-10-26
HUP0200827A3 (en) 2004-11-29
CA2370246C (en) 2017-03-21
KR20020008151A (ko) 2002-01-29
AU4222000A (en) 2000-11-02
EP1655368B1 (en) 2009-01-07
DE60041367D1 (de) 2009-02-26
EP1171594A1 (en) 2002-01-16
MXPA01010469A (es) 2002-07-30
HK1093218A1 (en) 2007-02-23
KR100634926B1 (ko) 2006-10-17
ATE329024T1 (de) 2006-06-15
ES2320367T3 (es) 2009-05-21
AU771042B2 (en) 2004-03-11
DE60028565T2 (de) 2007-06-06
US20060063203A1 (en) 2006-03-23
HU228898B1 (en) 2013-06-28
DE60028565D1 (de) 2006-07-20
ATE420177T1 (de) 2009-01-15
WO2000063380A1 (en) 2000-10-26
CN1328376C (zh) 2007-07-25

Similar Documents

Publication Publication Date Title
IL145675A (en) Vascular endothelial cell growth factor variants and uses thereof
EP2016953A3 (en) Vascular endothelial cell growth factor antagonists and uses thereof
BG103232A (en) Heterocyclic esters and amides
CA2095153A1 (en) Genetic modification of endothelial cells
ATE314395T1 (de) Humanisierte antikörper und verfahren zu ihrer herstellung
EP1746160A3 (en) Hepatocyte growth factor receptor antagonists and uses thereof
DK0851920T3 (da) Varianter af vaskulær endotelcellevækstfaktor, anvendelser af disse samt fremgangsmåder til fremstilling deraf
EP1650220A3 (en) Anti-VEGF antibodies
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
AU2001278797A1 (en) Expression vector using for animal cell
UA105625C2 (uk) Пастка vegf і її терапевтичне застосування
CA2158745A1 (en) Inhibitor of vascular endothelial cell growth factor
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
MX9604402A (es) Proteina similar a albumina serica humana.
CA2200980A1 (en) Mammalian receptors for modified low-density lipoprotein
EP1109454A4 (en) NEISSERIA MENINGITIDIS POLYPEPTID, NUCLEIC ACID SEQUENCE AND USES THEREOF
WO2000066731A3 (en) Recombinant laminin 5
DK0745122T3 (da) Galninreceptor, nukleinsyrer, transformerede celler og anvendelser heraf
DE59707813D1 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
WO2000053759A8 (en) Expression of human alpha-fetoprotein in mammalian cells

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 10 APR 2020 BY THOMSON REUTERS

Effective date: 20130514

EXPY Patent expired